Top

6550--Blood Cell Reagents

Active

36C24722Q0755Federal

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

The Government intends to award a sole source firm fixed price contract for the supply of red blood cell reagents to Ortho-Clinical Diagnostics Inc., located in Raritan, New Jersey. These reagents are essential for accurately testing, typing, and supplying blood and blood products at the WJB Dorn VA Medical Center in Columbia, South Carolina. The contract is expected to begin on October 1, 2022, and will consist of a one-year base period with four additional one-year option periods. The procurement is justified under the Federal Acquisition Regulation that allows sole source awards when only one supplier is capable of providing the required product. The Ortho Clinical Micro Typing System Workstations and Vision SWIFTs automated instruments, which are integral to the blood cell testing processes at the medical center, are proprietary to Ortho-Clinical Diagnostics. The reagents used with this equipment are FDA-approved and uniquely compatible, making it impossible to use alternatives with the existing systems. The reagents include specific items such as AFFIRMAGEN, SURGISCREEN, A2 CELLS, RESOLVE PANELS, and ALBAQ-CHECK for automated quality control. While this notice is not a request for proposals, interested parties may submit documentation of their capabilities for consideration, though the Government retains discretion over conducting competitive procurement. All communications regarding this contract must be directed to the Contracting Officer, Lasonja Harvey, by June 21, 2022.

General Info

Sole source contract to Ortho-Clinical for red blood cell reagents, starting October 2022.

Agency

Department Of Veterans Affairs → 247-NETWORK Contract Office 7 (36C247)

NAICS

325413 - In-Vitro Diagnostic Substance Manufacturing

Place of Performance

Set-Aside

NONE

Documents

36C24722Q0755 - Blood Cell Reagents

presolicitation

Low

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

PostedJun 15

special-notice

Ready to pursue this opportunity?

Get full access to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

AgencyDepartment Of Veterans Affairs → 247-NETWORK Contract Office 7 (36C247)

Contacts1 person available

OfficeAUGUSTA, GA, 30904, USA

Organization / AgencyDepartment Of Veterans Affairs → 247-NETWORK Contract Office 7 (36C247)

Office AddressAUGUSTA, GA, 30904, USA

Contacts

Lasonja HarveyContracting Officer

contact@example.gov

Full Description

INTENT TO SOLE SOURCE The Government hereby submits a notice of intent to award a sole source firm fixed price contract for red blood cell reagents to Ortho-Clinical Diagnostics Inc. at 1001 US Highway 202, Raritan NJ. The reagents will be used to properly test, type, and supply blood and blood products throughout the WJB Dorn VA Medical Center in Columbia South Carolina. The anticipated award will be for one base year with four, one-year option periods, effective October 1, 2022. The NAICS code for this requirement is 325413 and the small business size standard is 1,250 employees. The anticipated sole source award is in accordance with FAR13.106-1(b). A single source justification has been prepared. The facility owns and has installed the Ortho Clinical Micro Typing System Workstations and the Vision SWIFTs automated instruments, which are used to perform the blood cell tests. The instruments are proprietary to Ortho Clinical Diagnostics, Inc. The systems and reagents are FDA approved to work in unison to provide the patient test performed by the lab department. No other reagents are compatible nor approved to be performed on this equipment. The reagents include the following: 1. 0.8% AFFIRMAGEN (A1, B) 2. 0.8% SURGISCREEN (1,2,3) 3. A2 CELLS 3% 4. RESOLVE PANEL A, AB ID, SOLN,3ML,0.8% 5. RESOLVE PANEL B, AB ID, SOLN,3ML,0.8% 6. ALBAQ-CHECK (VISIONs AUTOMATED QC) This is NOT a request for quotes or proposals. However, all interested parties are encouraged to submit documentation demonstrating their capabilities to satisfy this requirement. The determination not to compete this requirement is solely within the discretion of the Government. Information received will normally be considered for the purposes of determining whether to conduct a competitive procurement. The Government will not be responsible for any costs incurred by responding to this notice. Only written responses will be considered. All questions, responses, or comments to this Notice of Intent should be directed to the Contracting Officer, Lasonja Harvey at contact@example.gov no later than June 21, 2022, at 1:00 PM ET. Please indicate in the subject line of your email: Notice of Intent - 36C24722Q0755, Blood Cell Reagents.